Lipocine Inc.
Close on Oct 19, 2026
- Market cap
- $12.57M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $190.00K | $-0.32 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.52 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $114.57K | $-0.59 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $622.85K | $-0.41 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 25, 2021 | After market close | – | – | – |
| Q3 FY2017 Ended Sep 30, 2017 | Nov 8, 2017 | Before market open | – | – | – |
| Q2 FY2017 Ended Jun 30, 2017 | Aug 7, 2017 | Before market open | – | – | – |
| Q1 FY2017 Ended Mar 31, 2017 | May 8, 2017 | Before market open | – | – | – |
| Q4 FY2016 Ended Dec 31, 2016 | Mar 6, 2017 | After market close | – | – | – |
Press releases
Announcements Lipocine filed with the SEC
Announces Health Canada Approval of TLANDO ® for Testosterone Replacement Therapy
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Other events · EX-99.1 to Form 8-K
to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Second Quarter Ended June 30, 2026
Results of operations · EX-99.1 to Form 8-K
Appoints Michael J. Grissinger to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Lipocine to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Other events · EX-99.1 to Form 8-K
to Present at A.G.P.’s Annual Virtual Healthcare Company Showcase
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Full Year Ended December 31, 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Other events · EX-99.1 to Form 8-K
PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Third quarter Ended September 30, 2025
Results of operations · EX-99.1 to Form 8-K
Presents LPCN 2401 Clinical Data at ObesityWeek ®
Other events · EX-99.1 to Form 8-K
Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
to Present at H.C. Wainwright 27 th Annual Global Investment Conference
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Second Quarter Ended June 30, 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Other events · EX-99.1 to Form 8-K
to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO TM )
Other events · EX-99.1 to Form 8-K
Announces Filing of New Drug Submission for TLANDO ® in Canada
Other events · EX-99.1 to Form 8-K